SLStephan Ladisch

Stephan Ladisch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephan Ladisch has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Central nervous system involvement in children with hemophagocytic lymphohistiocytosis: an HLH-2004 study report

    by Elisabet Bergsten, Maurizio Aricó, Itziar Astigarraga, Eiichi Ishii, Gritta Janka, Stephan Ladisch, Kai Lehmberg, Kenneth L. McClain, Milen Minkov, Vasanta Nanduri, et al.

    Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with an inherited form (primary HLH [pHLH]), of which familial HLH (FHL) is most prevalent, and an acquired (non-Mendelian) form (secondary HLH); both potentially fatal. As more patients survive, evaluating long-term morbidity, especially neurological complications, is important. Here, we report on central nervous system involvement at onset, its impact on mortality and morbidity, and long-term follow-up in 365 children aged <18 years enrolled in the prospective multinational HLH-2004 study. This treatment included etoposide; dexamethasone; cyclosporine; and, for selected patients, intrathecal methotrexate/prednisolone; followed by hematopoietic stem cell transplantation (HSCT) for pHLH. At diagnosis, 33% had neurological symptoms and 57% abnormal cerebral spinal fluid (CSF); 33% and 73%, respectively, in children with verified FHL. Elevated CSF protein was associated with inferior survival in univariate analyses, and multivariate analyses revealed reduced survival in children with both neurological symptoms and abnormal CSF. Overall, 32% of post-HSCT long-term survivors had neurological symptoms at last follow-up, more often in children with abnormal CSF at diagnosis; psychomotor retardation affected 25%, seizures 11%, and attention deficit hyperactivity disorder (ADHD)/autism 10% (at least). Seizures and psychomotor retardation were detected before HSCT in approximately half of children who received HSCT; however, at least 3 years after HSCT in one-third. The median time for reporting ADHD/autism was 5 years after HSCT. Late neurological complications were reported in 7% of long-term survivors without HSCT. In conclusion, late neurological complications remain a major concern in pHLH, CSF evaluation at diagnosis is valuable, and long follow-up is important because complications may be diagnosed late. This trial was registered at www.clinicaltrials.gov as #NCT00426101.

  • Open Access

    Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis

    by Itziar Astigarraga, Helga Arnardottir, Oussama Abla, Maurizio Arico, Jorge Braier, Jean Donadieu, Nicole Grois, Jan-Inge Henter, Stephan Ladisch, Thomas Lehrnbecher, et al.

    Langerhans cell histiocytosis (LCH) confined to the skeleton has excellent survival, yet optimal management of multifocal bone disease and lesions at traditionally defined “special sites” remains uncertain due to limited prospective data. We report prospective results from an international pilot trial embedded within the Histiocyte Society LCH-III study (2001-2008) evaluating 6 months of vinblastine-prednisolone in children with single-system skeletal LCH. Among 455 enrolled patients, 381 were evaluable. Early response at week 6 was achieved in 83% of cases. Five-year overall survival was 100%, and event-free survival (EFS) was 71%. Multifocal bone lesions (MFB) were the dominant predictor of relapse (5-year EFS: 63% vs 87% without MFB; P< .001), whereas isolated central nervous system (CNS)-risk skeletal lesions did not independently affect EFS. In contrast, the cumulative incidence of central diabetes insipidus at 5 years was 5% overall but was significantly higher in patients with CNS-risk lesions, particularly when combined with MFB. These prospective data demonstrate that in single-system skeletal LCH, disease extent and lesion location confer distinct risks, with skeletal multiplicity determining relapse propensity, and anatomic location determining the risk of permanent endocrine sequelae. This study provides a prospective international benchmark for systemic therapy and supports risk-adapted treatment strategies that minimize long-term morbidity while avoiding unnecessary treatment escalation. This trial was registered at www.ClinicalTrials.gov as NCT00276757.

  • Open Access

    Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis

    by Barbara A. Degar, Oussama Abla, Patrick K. Campbell, Alison M Friedmann, Michael M Henry, Michele L. Hermiston, Michael D. Hogarty, Eric D. Jacobsen, Rima Jubran, Pei-Chi Kao, et al.

    Langerhans cell histiocytosis (LCH) and non-LC histiocytosis are rare neoplastic diseases with variable behavior. Although chemotherapy is effective in many patients, disease recurrence is common, and some patients respond poorly to treatment and/or experience long-term morbidity and mortality. Clofarabine (Clolar), a deoxyadenosine analog, has shown encouraging activity in histiocytic disorders. Here, we report the first prospective, multicenter, phase II study (NCT02425904) evaluating the efficacy and toxicity of clofarabine in recurrent/refractory (R/R) LCH (Stratum 1) and non-LC histiocytosis (Stratum 2). All participants received clofarabine on days 1-5 of each 28-day cycle. Response was assessed after 2 cycles; participants without evidence of disease progression received 4 additional cycles. Twenty-five participants enrolled: 20 in Stratum 1, five in Stratum 2 (including one patient later deemed inevaluable). In Stratum 1, 17/20 participants (85%; 95% CI: [62%, 97%]) were responders, and three had stable disease after cycle 2. Nineteen Stratum 1 participants completed 6 cycles; one withdrew after cycle 3. No Stratum 1 participants progressed during treatment and three had residual or recurrent disease after cycle 6, resulting in 2-year PFS ± SE and OS of 89±7% and 100%, respectively (n=20; median follow-up: 40.9; range: 2.7-49.4). In Stratum 2, 3/4 participants (75%; 95% CI: [19%, 99%]) had partial response. Overall, 80% (20/25) of participants had one or more grade ≥3 toxicities attributed to protocol therapy. In conclusion, clofarabine is active and tolerable in children with R/R LCH and warrants further study in patients with non-LC histiocytosis. Further study of clofarabine in these populations is warranted.


  • Open Access

    Langerhans cell histiocytosis: progress and controversies

    by Oussama Abla, Barrett Rollins, Stephan Ladisch


  • IFN-γ and tumor gangliosides: Implications for the tumor microenvironment

    by Barbara Dillinger, Sarah Ahmadi-Erber, Manuel Lau, Markus A. Hoelzl, Friedrich Erhart, Birgit Juergens, Dietmar Fuchs, Andreas Heitger, Stephan Ladisch, Alexander M. Dohnal


  • Open Access

    How I treat Langerhans cell histiocytosis

    by Carl E. Allen, Stephan Ladisch, Kenneth L. McClain

    “Langerhans cell histiocytosis” (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a+/CD207+ dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.


  • Open Access

    New Approaches to the Molecular Biology, Classification, and Therapy of Nervous System Tumors

    by Albert J. Wong, Martin Padarathsingh, David N. Louis, Sandra Rempel, Stephan Ladisch, Candece Gladson


  • Structural characterization andin vivo immunosuppressive activity of neuroblastoma GD2

    by Ruixiang Li, Douglas Gage, Robert Mckallip, Stephan Ladisch

    Shedding of neuroblastoma gangliosides is positively correlated with tumour progression in patients with neuroblastoma. In assessing the biological activity of these ganglioside molecules, we recently found that total human neuroblastoma gangliosides inhibit cellular immune responses. Here, we have studied the major neuroblastoma ganglioside, GD2. GD2 was purified by high performance liquid chromatography and structurally characterized by mass spectrometry. Immunoregulatory effects of GD2 in vivo were then determined in an established murine model. GD2 significantly downregulated the local cellular immune response to an allogeneic cell challenge; the usual increase in mass of the lymph node draining the injection site was reduced by 88%, from 1.52 to 0.19 mg (control versus GD2-treated mice;p6 cells, and lymphocyte DNA synthesis was reduced to half of the control level. These results show that certain shed tumour gangliosides, such as GD2, function as intercellular signalling molecules, downregulate the cellular immune response, and may thereby enhance tumour formation and progression.